Rabeprazole sodium 是一种质子泵抑制剂，不可逆地抑制胃 H+/K+-ATPase，可研究胃溃疡和胃食管反流。它诱导细胞凋亡，也抑制尿苷核苷核糖水解酶 ，IC50为 0.3 μM。

Rabeprazole sodium is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.

Administration of rabeprazole leads to a marked decrease in the viability of MKN-28 cells. Exposure to rabeprazole induces significant apoptosis in AGS cells. Rabeprazole completely inhibits the phosphorylation of ERK 1/2 in the MKN-28 cells, whereas the same effect is not observed in either the KATO III or MKN-45 cells. Rabeprazole is able to efficaciously inhibit the phosphorylation of ERK 1/2 in the gastric cancer cells.Thus, rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 signaling pathway[2].

Rabeprazole does not appear to exacerbate bone metabolic disorders in gastrectomized rats, but rather ameliorates the TG-induced BMD decrease[1].

Rabeprazole is administrated to three gastric cancer cell lines, KATO III, MKN-28 and MKN-45, at a dosage of 0.2 mM for 16 h. The viability of these cells is determined by a trypan blue exclusion assay.(Only for Reference)

117976-90-6

C18H20N3NaO3S

381.43

雷贝拉唑钠;Habeprazole Sodium;Dexrabeprazole Sodium;Rebeprazole sodium;Aciphex Sodium;LY307640 sodium

H2O:70 mg/mL (183.5 mM)
Ethanol:71 mg/mL (186.1 mM)
DMSO:71 mg/mL (186.1 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years